<DOC>
	<DOCNO>NCT00002569</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without chemotherapy treat patient anaplastic oligodendroglioma .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Treating Patients With Anaplastic Oligodendroglioma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival time tumor progression patient unifocal multifocal , supratentorial , pure mixed anaplastic oligodendroglioma treat radiotherapy without procarbazine , lomustine , vincristine ( PCV ) . - Compare toxic effect 2 regimen patient . - Compare quality life neurologic function patient treat 2 regimen . OUTLINE : This randomize study . Patients stratified age ( 50 vs 50 ) , Karnofsky performance status ( 60-70 % vs 80-100 % ) , tumor grade ( moderately vs highly anaplastic ) . Within 8 week diagnostic surgery , patient randomize 1 2 treatment arm . - Arm I : Within 2 week randomization , patient receive oral lomustine day 1 , oral procarbazine day 8-21 , vincristine IV day 8 29 ( PCV ) . Treatment continue every 6 week 4 course absence disease progression unacceptable toxicity . Beginning within 6 week day 29 course 4 , patient undergo radiotherapy 5 day week 5.6 week follow boost radiotherapy 5 day week 1 week . - Arm II : Within 2 week randomization , patient undergo radiotherapy arm I . Quality life assess baseline ; time CT MRI scan study ; every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter completion study therapy . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 292 patient ( 146 per arm ) accrue study within 5.4 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unifocal multifocal , supratentorial , pure mixed anaplastic oligodendroglioma Prior suspect proven lowgrade glioma allow current histologic proof pure mixed anaplastic oligodendroglioma Tumor must contain unequivocal ( least 25 % ) oligodendroglial element 2 anaplastic feature , 1 must frequent mitoses endothelial proliferation For mixed tumor , nonoligodendroglial element must astrocytic oligodendroglial astroglial component may anaplastic No evidence spinal drop metastasis spread noncontiguous meninges MRI spine require asymptomatic patient patient exclude base pathologic evidence local meningeal infiltration underlie tumor No tumor predominantly locate posterior fossa ( i.e. , brainstem cerebellum ) No spinal cord tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 2 time normal Serum glutamate oxaloacetate transaminase ( SGOT ) great 2 time normal Alkaline phosphatase great 2 time normal Renal : Creatinine great 1.5 time normal Pulmonary : No chronic lung disease unless diffusion capacity lung carbon monoxide ( DLCO ) least 60 % predict Other : No active infection No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent steroid antiemetic Concurrent steroid allow control central nervous system ( CNS ) symptom due tumorassociated radiotherapyassociated cerebral edema Radiotherapy : No prior radiotherapy brain head/neck Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>